Ichor is a privately held emerging biotechnology company, leveraging its proprietary TriGrid™
System to enable electroporation-mediated DNA drug products.

Ichor has raised paid-in capital from equity financing from undisclosed private and institutional
investors. The company has leveraged a mix of corporate and academic collaborations and grant and contract
funding to advance the technology for a variety of applications. To date, Ichor has received
committed grant or contract funding in excess of $30 million and has applied for significant
additional funding.

As a privately held company, Ichor does not disclose detailed financial information.

Copyright 2004 Ichor Medical Systems. All rights reserved. Site designed by Bioviz. Developed by Kanoa.